IFM THERAPEUTICS
IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
IFM THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.ifmthera.com
Total Employee:
11+
Status:
Active
Contact:
857-327-9903
Email Addresses:
[email protected]
Total Funding:
82.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Google Tag Manager Mobile Non Scaleable Content Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
InVivo Therapeutics
InVivo Therapeutics is a medical device company focused on developing restoration treatments for patients with spinal cord-injuries.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Monopar
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Investors List
Abingworth
Abingworth investment in Venture Round - IFM Therapeutics
Atlas Venture
Atlas Venture investment in Venture Round - IFM Therapeutics
Omega Funds
Omega Funds investment in Venture Round - IFM Therapeutics
Novartis
Novartis investment in Series A - IFM Therapeutics
Abingworth
Abingworth investment in Series A - IFM Therapeutics
Atlas Venture
Atlas Venture investment in Series A - IFM Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-01-07 | Magenta’s Cooke Joins IFM Therapeutics as Chief Scientific Officer |
| 2019-12-02 | IFM gets new CEO, bags another $55M to launch incubator, new subsidiaries |
Official Site Inspections
http://www.ifmthera.com
- Host name: 219.104.215.35.bc.googleusercontent.com
- IP address: 35.215.104.219
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "IFM Therapeutics"
About Us | IFM Therapeutics
IFM Therapeutics is pursuing a number of separate programs, each targeting key control nodes of the innate immune system. IFM Therapeutics places each program (or set of related programs) in its own dedicated, independently …See details»
IFM Therapeutics - Wikipedia
IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases. IFM Therapeutics launched in 2015 in Cambridge, Massachusetts, based on seed funding from the Boston-based venture capital fund Atlas Venture. The company's founding involved seven people, a mix of executives and university professors. Series A financing was provided by Atlas, London …See details»
IFM Therapeutics - Crunchbase Company Profile & Funding
IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate …See details»
Novartis Acquires IFM Due to Develop First-In-Class STING …
Mar 13, 2024 IFM places each program in its own dedicated, independently financed, R&D-focused subsidiary company, which is supported by the common infrastructure, management …See details»
IFM Therapeutics - LinkedIn
IFM Therapeutics | 2,084 followers on LinkedIn. At IFM Therapeutics, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative …See details»
IFM Therapeutics Company Profile 2024: Valuation, Investors ...
IFM Therapeutics General Information Description. Developer of small molecule medicines designed to transform immunotherapy. The company's medicines precisely target the innate …See details»
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief …
Jan 7, 2020 Dr. Cooke joins IFM from Magenta Therapeutics where he most recently served as Chief Scientific Officer, leading an organization responsible for developing curative medicines …See details»
Bristol Myers Squibb - Bristol-Myers Squibb Completes Previously ...
Sep 7, 2017 Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction …See details»
IFM Therapeutics Announces Extension of Collaboration …
Dec 1, 2021 IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due Continued research and development collaboration is advancing …See details»
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3
Apr 1, 2019 For more information, please visit www.ifmthera.com. Media Contact Cherise Adkins Spectrum Science P: (+1) 202-587-2507 [email protected]. Investor Contact …See details»
IFM Therapeutics - VentureRadar
Website: https://www.ifmthera.com. Develops drugs targeting the innate immune system to treat inflammatory and autoimmune disorders and cancer, potentially improving immune response …See details»
IFM Therapeutics and Novartis Complete Previously Announced …
BOSTON, May 8, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in …See details»
IFM Therapeutics and Novartis Complete Previously Announced …
May 8, 2019 For more information, please visit www.ifmthera.com. Media Contact Cherise Adkins Spectrum Science P: (+1) 202-587-2507 [email protected]. Investor …See details»
IFM Therapeutics - Overview, News & Similar companies - ZoomInfo
Nov 30, 2021 Who is IFM Therapeutics. IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases. IFM Therapeutics launched in …See details»
IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 …
Jul 19, 2018 IFM’s team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, auto-immunity, …See details»
Novartis to acquire inflammasome-focused IFM Tre
Apr 1, 2019 The NLRP3 (nucleotide-binding domain, leucine-rich repeat-containing receptor pyrin domain containing 3) inflammasome is a multiprotein complex that is part of the innate …See details»
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 …
BOSTON, April 1, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in …See details»
Research | IFM Therapeutics
The majority of advances in immunotherapy have focused on targeting the adaptive immune system; however, many patients do not respond to treatment, others lose responsiveness, and …See details»
IFM Therapeutics Announces $55.5 Million Financing to Launch …
BOSTON, Dec. 2, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in …See details»